MedImmune, the global biologics research and development arm of AstraZeneca, today announced that it has achieved a significant scientific milestone by publishing three manuscripts in Nature Immunology that advance the understanding of the immune system and highlight underlying mechanisms in two little-understood disease areas — chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus (SLE). These include:
{iframe}http://www.eurekalert.org/pub_releases/2016-04/mi-nsp042516.php{/iframe}